Clinical Trial Update: Efficacy and Safety of Ropeginterferon Alfa 2b (P1101) for Patients With Polycythemia Vera [Phase 4]

View source ↗

Summary

This clinical trial update reports on a Phase 4 study of Ropeginterferon alfa-2b (P1101) for polycythemia vera, focusing on efficacy and safety, with the trial …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myeloproliferative Neoplasm
• Polycythemia Vera

Drugs mentioned

• Ropeginterferon alfa-2b (P1101) (ropeginterferon alfa-2b)

Snippet

Sponsor: PharmaEssentia | Conditions: Polycythemia Vera, Myeloproliferative Neoplasm | Phase 4 | Status: NOT_YET_RECRUITING